These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34003484)

  • 21. Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?
    Zamora B; Garrison LP; Unuigbe A; Towse A
    Cost Eff Resour Alloc; 2021 Mar; 19(1):13. PubMed ID: 33648523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING.
    Roldán ÚB; Badia X; Marcos-Rodríguez JA; de la Cruz-Merino L; Gómez-González J; Melcón-de Dios A; Caraballo-Camacho MO; Cordero-Ramos J; Alvarado-Fernández MD; Galiana-Auchel JM; Calleja-Hernández MÁ
    Int J Technol Assess Health Care; 2018 Jan; 34(5):519-526. PubMed ID: 30348241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.
    Schey C; Postma MJ; Krabbe PFM; Topachevskyi O; Volovyk A; Connolly M
    Front Public Health; 2020; 8():162. PubMed ID: 32457865
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors.
    Bao Y; Gao B; Meng M; Ge B; Yang Y; Ding C; Shi B; Tian L
    BMC Health Serv Res; 2021 Aug; 21(1):807. PubMed ID: 34384428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment of a value assessment framework for orphan medicinal products in China.
    Chen H; Xiang Y; Tang X; Hu M
    Orphanet J Rare Dis; 2024 Oct; 19(1):390. PubMed ID: 39428462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art.
    Oliveira MD; Mataloto I; Kanavos P
    Eur J Health Econ; 2019 Aug; 20(6):891-918. PubMed ID: 31006056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review.
    Moreno-Calderón A; Tong TS; Thokala P
    Pharmacoeconomics; 2020 Mar; 38(3):269-283. PubMed ID: 31820294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicriteria decision analysis (MCDA) tool to purchase implantable medical devices in Egypt.
    Elezbawy B; Fasseeh AN; Németh B; Gamal M; Eldebeiky M; Refaat R; Taha A; Rabiea S; Abdallah M; Ramadan S; Noaman H; Eldin AB; Mostafa H; Nouh S; Zaki A; Abdelrahman M; Abaza S; Kalò Z
    BMC Med Inform Decis Mak; 2022 Nov; 22(1):289. PubMed ID: 36352382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How can multi criteria decision analysis support value assessment of pharmaceuticals? - Findings from a systematic literature review.
    Kolasa K; Zah V; Kowalczyk M
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):379-391. PubMed ID: 29707985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.
    Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z
    BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.
    Gilabert-Perramon A; Torrent-Farnell J; Catalan A; Prat A; Fontanet M; Puig-Peiró R; Merino-Montero S; Khoury H; Goetghebeur MM; Badia X
    Int J Technol Assess Health Care; 2017 Jan; 33(1):111-120. PubMed ID: 28434413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).
    de Andrés-Nogales F; Cruz E; Calleja MÁ; Delgado O; Gorgas MQ; Espín J; Mestre-Ferrándiz J; Palau F; Ancochea A; Arce R; Domínguez-Hernández R; Casado MÁ;
    Orphanet J Rare Dis; 2021 Apr; 16(1):186. PubMed ID: 33902672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review and classification of approaches for dealing with uncertainty in multi-criteria decision analysis for healthcare decisions.
    Broekhuizen H; Groothuis-Oudshoorn CG; van Til JA; Hummel JM; IJzerman MJ
    Pharmacoeconomics; 2015 May; 33(5):445-55. PubMed ID: 25630758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Group cognitive behavioural therapy for postnatal depression: a systematic review of clinical effectiveness, cost-effectiveness and value of information analyses.
    Stevenson MD; Scope A; Sutcliffe PA; Booth A; Slade P; Parry G; Saxon D; Kalthenthaler E;
    Health Technol Assess; 2010 Sep; 14(44):1-107, iii-iv. PubMed ID: 20863477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study.
    Wahlster P; Goetghebeur M; Schaller S; Kriza C; Kolominsky-Rabas P;
    Health Res Policy Syst; 2015 Apr; 13():24. PubMed ID: 25928535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation.
    Fraser H; Gallacher D; Achana F; Court R; Taylor-Phillips S; Nduka C; Stinton C; Willans R; Gill P; Mistry H
    Health Technol Assess; 2020 Jun; 24(31):1-232. PubMed ID: 32605705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.
    Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K
    Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.